Anna PaganiAnna Pagani is an Italian architect and PhD candidate (C. Binder, HERUS). In 2015 she graduates cum laude in Architecture and Building Engineering at both Politecnico di Torino and Politecnico di Milano in Italy. She obtains a Double-Master Degree for technology talents (ASP-Alta Scuola Politecnica) with a multidisciplinary thesis about the Turin Energy Centre.During her academic path she is the winner of multiple European Union scholarships, allowing her to study in Barcelona and Lausanne. Her Master Thesis entitled “Hutongs-Transformation: A Battle Between Memories” (2015) is awarded with honors by the Politecnico di Torino.Following the path of anthropology, architecture, and sustainability, Anna is the curator of the seminar “Chinese New TOwns: negotiating citizenship and physical form” at the Beijing Design Week 2016.In 2017 she moves to China and works as architect for DEDODESIGN, a sino-italian architectural and design firm based in Shanghai, which focuses on sustainable architecture projects. During her stay, she is the organizer of two international workshops around the topics of sustainability.Aside from university..Anna studies since the age of 4 in the Lycée Français Jean Giono in Torino, which allowed her to speak, today, 6 languages. With a strong passion for writing, she has published on the Italian Review Edizioni Zero, il Giornale dell’Architettura, as well as Babylon.When she's not in the office, Anna practices yoga every morning, dances contemporary dance, sings in a choir, studies German, and attempts to limit her environmental footprint...
Valentin Daniel Maurice BourdonValentin Bourdon est architecte Dr EPFL, chercheur postdoctorant et assistant d'enseignement. Il obtient son diplôme d'architecture en juillet 2013 à l’École d’Architecture de la Ville et des Territoires Paris-Est à Marne-la-Vallée sous la direction de Jacques Lucan, et son doctorat en septembre 2020 à l’EPFL sous la direction de Luca Ortelli. Depuis septembre 2021, il est coordinateur exécutif du Habitat Research Center et coordinateur du programme MAS ETH EPFL UTD. Engagé dans les recherches du Laboratoire de Construction et Conservation entre janvier 2017 et septembre 2021, il participe aussi à l'encadrement de l'atelier Housing - Théorie et critique du projet, en troisième année d'architecture. En 2019 il bénéficie d'un séjour académique de six mois au sein du Metrolab Bruxelles grâce au soutien du FNS, et multiplie pendant sa recherche les publications scientifiques et à destination du grand public. Son arrivée en Suisse et son retour dans le monde académique interviennent après une expérience professionnelle approfondie au sein de l’agence parisienne MGAU Michel Guthmann Architecture Urbanisme. De 2010 à 2016, il participe à la majorité des projets développés par l'agence et assure le suivi de plusieurs d'entre eux, aussi bien des logements collectifs que des projets urbains. Il est architecte habilité à exercer la maîtrise d’œuvre en son nom propre depuis janvier 2015.
Hilal Lashuel2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies. Patrick AebischerPatrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Mihai Adrian IonescuD'origine et de nationalités roumaine et suisse, Mihai-Adrian Ionescu est né en 1965. Après le doctorat en Physique des Composants à Semiconducteurs de lInstitut National Polytechnique de Grenoble, M. Ionescu a travaillé comme chercheur post-doctoral au LETI-CEA Grenoble, sur la caractérisation des diélectriques low-k pour les technologies submicroniques CMOS. Après une courte période au sein du CNRS, comme chargé de recherche 1ere Classe il a effectué un séjour post-doctoral au Center for Integrated Systems, Stanford University, USA. Actuellement il est Professeur Nanoélectronique à lEcole Polytechnique Fédérale de Lausanne.
